Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith certificate dated 1st July, 2020 issued by M/s. Purva Shregistey India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company confirming the compliances of regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2020. Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1010 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer Parmax Pharma Ltd - 540359 - Closure of Trading Window
In continuation to our letter dated 30th March, 2020 intimating closure of Trading Window of the Company w.e.f. 1st April, 2020 till 48 hours after the declaration of Audited Financial Results for the financial year ended on 31st March, 2020. In this regard, we hereby inform that the Audited Financial Results for the financial year ended on 31st March, 2020 are yet to be submitted in view of extension given by SEBI vide its circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/106 dated 24th June, 2020 and hence, in compliance with BSE''s Circular No. LIST/COMP/O1/2019-20 dated 2"" April, 2019 and Company''s Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and SEBI (Prohibition of Insider Trading) Regulations, 2015 the 'Trading Window' of the Company shall continue to remain closed till 48 hours after the declaration of Unaudited Financial Results for the quarter ended on 30th June, 2020. Parmax Pharma Ltd - 540359 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2020.
Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the certificate received from Mr. Samsad Alam Khan, Practicing Company Secretary, for the half-year ended 31st March, 2020 confirming the compliance of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith certificate dated 2nd April, 2020 issued by M/s. Purva Shregistry India Private Limited, Registrar and Share Transfer Agent (RTA) of the Company confirming the compliances of regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2020. Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended March 31, 2020
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click here Parmax Pharma Ltd - 540359 - Update Regarding Production Of Intermediates Of 'Hydroxy Chloroquine'.
Dear Sir, We hereby informing that the Company has recently entered a Confidentiality Agreement with Cadila Healthcare Limited (the CHL), Ahmedabad for production of intermediates of 'Hydroxy chloroquine' ('Product') on the basis of process and specifications provided by the CHL. Currently Company is reviewing the Business and taking trial batches of the Product. Further Company is in business of manufacturing of Pharmaceutical Drug Intermediates, Bulk Drugs and Speciality chemicals hence production of intermediates of 'Hydroxy chloroquine' is general character and nature of our business and it is not material events as specified in Part B of Schedule III, read with Regulation 30(4) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. Company is voluntarily making this disclosure as per good corporate governance practice. Copy of news article published in Divya Bhaskar, Rajkot dated 25th April, 2020 containing this coverage is also attached herewith. Parmax Pharma Ltd - 540359 - Compliance Certificate Pursuant To Regulation 7(3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 For The Year Ended On 31St March, 2020.
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that all activities in relation to both physical and electronic share transfer facility are maintained during the period of 1st October 2019 to 31st March, 2020 (both days inclusive) by the Company''s Registrar and Share Transfer Agent, i.e. M/s Purva Sharegistry India Pvt. Ltd., having its Office at Unit no. 9, Shiv Shakti Ind. Estt. J .R. Boricha Marg, Lower Parel (E), Mumbai 400 011. Further, we confirm that M/s Purva Sharegistry India Pvt. Ltd. is registered as Permanent Category- / Registrar and Transfer Agent with the Securities and Exchange Board of India (SEBI Registration no. INROO0001112). Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0101 Name of the Signatory :- Yash VoraDesignation :- Company Secretary and Compliance Officer Parmax Pharma Ltd - 540359 - Closure of Trading Window
Dear Sir/Madam, This is to inform you that pursuant to Company's Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and SEBI (Prohibition of Insider Trading) Regulations, 2015, 'Trading Window' for dealing in securities of the Company will remain closed with effect from 1st April, 2020 till 48 hours after the declaration of financial results for the Quarter and financial year ended 31st March, 2020. The date of announcement of the financial results for the quarter and financial year ending 31st March, 2020 shall be announced in due course you are requested to take the same on your records.